PMID- 33565277
OWN - NLM
STAT- MEDLINE
DCOM- 20211119
LR  - 20211119
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 12
IP  - 7
DP  - 2021 Apr
TI  - ALK-rearranged squamous cell carcinoma of the lung.
PG  - 1106-1114
LID - 10.1111/1759-7714.13818 [doi]
AB  - BACKGROUND: ALK rearrangement is a very rare subset of squamous cell carcinoma 
      (SCC) and one of the clinical features in patients is lack of data. Here, we 
      report eight patients diagnosed with SCC of the lung harboring ALK rearrangement. 
      METHODS: We collected primary NSCLC samples at the Beijing Chest Hospital between 
      January 2012 and December 2018 for Ventana (D5F3) immunohistochemical detection. 
      Among the 148 patients was diagnosed ALK-rearranged non small cell lung cancer 
      (NSCLC), only eight cases was SCC. We collected patients information from 
      electronic patent records (EPRs). RESULTS: The eight cases of SCC were diagnosed 
      by immunohistochemistry (IHC). Two were given crizotinib as second-line therapy. 
      One patient had stable disease (SD) and progression-free survival (PFS) of six 
      months. The other patient had progressive disease (PD) but PFS was only one 
      month. The side effects were tolerable. This report identified 31 cases of ALK 
      rearrangement in SCC patients from a literature search (including the eight 
      patients in this study). These fusion genes are often seen in a younger age group 
      (mean age: 55.6 years) and non-smokers (18/31, 58.1%). A total of 20 cases 
      received an ALK inhibitor as first- or second-line treatment which included 11 
      with a partial response (PR), four with SD, and five with PD. The DCR and ORR was 
      75.0% (15/20) and 55.0% (11/20), respectively. The median duration time of 
      therapy was 6.4 +/- 4.4 months. CONCLUSIONS: Patients with ALK-rearranged SCC 
      obtained clinical benefit from ALK-inhibitor therapy, especially those who were 
      non-smokers and whose tumors had been identified by IHC+/FISH+.
CI  - (c) 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Meng, Qiyi
AU  - Meng Q
AD  - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical 
      University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 
      China.
FAU - Dong, Yujie
AU  - Dong Y
AD  - Department of Pathology, Beijing Chest Hospital, Capital Medical University, 
      Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
FAU - Tao, Hong
AU  - Tao H
AD  - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical 
      University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 
      China.
FAU - Shi, Liang
AU  - Shi L
AD  - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical 
      University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 
      China.
FAU - Tong, Li
AU  - Tong L
AD  - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical 
      University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 
      China.
FAU - Tang, Junfang
AU  - Tang J
AD  - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical 
      University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 
      China.
FAU - Zhang, Shucai
AU  - Zhang S
AD  - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical 
      University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 
      China.
FAU - Liu, Zhe
AU  - Liu Z
AD  - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical 
      University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 
      China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20210209
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anaplastic Lymphoma Kinase/*metabolism
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*genetics/pathology
MH  - Male
MH  - Middle Aged
PMC - PMC8017260
OTO - NOTNLM
OT  - ALK inhibitor drug
OT  - ALK rearrangement
OT  - PDL1
OT  - immunotherapy
OT  - squamous cell carcinoma
EDAT- 2021/02/11 06:00
MHDA- 2021/11/20 06:00
PMCR- 2021/04/01
CRDT- 2021/02/10 06:04
PHST- 2020/12/15 00:00 [revised]
PHST- 2020/10/30 00:00 [received]
PHST- 2020/12/15 00:00 [accepted]
PHST- 2021/02/11 06:00 [pubmed]
PHST- 2021/11/20 06:00 [medline]
PHST- 2021/02/10 06:04 [entrez]
PHST- 2021/04/01 00:00 [pmc-release]
AID - TCA13818 [pii]
AID - 10.1111/1759-7714.13818 [doi]
PST - ppublish
SO  - Thorac Cancer. 2021 Apr;12(7):1106-1114. doi: 10.1111/1759-7714.13818. Epub 2021 
      Feb 9.